HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Neurocrine Biosciences (NBIX) and raises the price target from $150 to $160.
May 02, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Neurocrine Biosciences and increases the price target to $160.
The upgrade in the price target from $150 to $160 by HC Wainwright & Co. reflects a positive outlook on Neurocrine Biosciences, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100